# Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

> **NCT00161837** · PHASE2,PHASE3 · COMPLETED · sponsor: **Alachua Government Services, Inc.**

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Vero Cell-derived Influenza Vaccine
- **BIOLOGICAL:** Egg-derived Influenza Vaccine

## Key facts

- **NCT ID:** NCT00161837
- **Lead sponsor:** Alachua Government Services, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** — (—)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00161837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00161837, "Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00161837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*